Irinotesin (Irinotecan Hydrochloride Trihydrate)

Irinotecan is a pro‑drug that is metabolised inside cancer cells to SN‑38, which binds to topoisomerase I. This prevents the re‑ligation of single‑strand DNA breaks during replication, causing accumulation of DNA damage and triggering apoptosis of rapidly dividing tumour cells.

The dose of Irinotesin is individualized and set by the treating oncologist based on factors such as disease stage, patient weight, performance status and prior therapies. Specific dosing regimens are not disclosed publicly and must follow the prescriber’s written order.

Irinotecan is classified as contraindicated during pregnancy and lactation unless the potential benefit to the mother outweighs the risk to the fetus or infant. Animal studies have shown embryotoxic effects, and limited human data suggest potential harm, so it should be avoided in these situations.

To request Irinotesin, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where required) and any necessary import documentation.

The most common alternative to irinotecan is topotecan, another topoisomerase I inhibitor, which is generally used for ovarian and small‑cell lung cancers. Compared with topotecan, irinotecan has a broader evidence base in colorectal cancer and is often combined with fluoropyrimidines, whereas topotecan is administered on a different schedule and has a distinct toxicity profile.

Irinotesin should be stored at 2‑8 °C in a refrigerator, protected from light. The vial must not be frozen or shaken. Before reconstitution, inspect the product for particulate matter and discoloration, and use aseptic technique to prepare the sterile solution for intravenous infusion.

Irinotesin is administered by intravenous infusion. After reconstitution, the solution is diluted in an appropriate IV fluid and infused over a period defined by the prescribing oncologist, typically ranging from 30 minutes to several hours, depending on the treatment protocol.

The most serious adverse events include severe neutropenia with fever (febrile neutropenia), life‑threatening diarrhea that can lead to colitis or intestinal perforation, and hypersensitivity reactions such as anaphylaxis. Prompt medical evaluation is essential if any of these symptoms develop.

Irinotesin should not be used in patients with known hypersensitivity to irinotecan or any of its excipients, in those with uncontrolled infections, or in individuals who are pregnant or breastfeeding unless absolutely necessary. Caution is also advised for patients with severe hepatic impairment or pre‑existing bone‑marrow suppression.